Avantor, Inc. reports developments as a life science tools company supplying mission-critical products and services to life sciences and advanced technology customers through its VWR Distribution & Services and Bioscience & Medtech Products businesses. Recurring updates cover earnings, cash flow, leverage, guidance, segment performance and the company’s Revival transformation program, including VWR brand activity, manufacturing and supply-chain improvements and e-commerce upgrades.
Company news also covers portfolio and infrastructure actions such as Masterflex fluid handling systems, single-use assemblies, peristaltic pumps, J.T. Baker high-purity process chemicals, and expanded microbial and stability testing capabilities for regulated biopharma manufacturing. Governance and management updates include finance leadership changes and appointments tied to bioscience, medtech products and enterprise transformation.
Avantor, Inc. (NYSE: AVTR) reported strong financial results for Q1 2021, with net sales of $1.79 billion, a 17.5% increase year-over-year. Net income surged 248.9% to $164 million, while adjusted EBITDA rose 38.2% to $363.1 million. The company achieved an adjusted net leverage of 3.5x. Significant growth was seen across all regions, particularly in AMEA, which experienced a 32.0% increase in net sales. The acquisition of Ritter is expected to enhance Avantor's product offerings. The company is on track to exceed $800 million in free cash flow for the year.
Avantor (NYSE: AVTR) will participate in a virtual fireside chat at the BofA Securities 2021 Virtual Health Care Conference on May 11, 2021. Michael Stubblefield, President and CEO, will represent the company, beginning at approximately 9:30 a.m. EDT. The event will be accessible via a live webcast on Avantor's investor relations website and will be available for replay until May 31, 2021. Avantor is a leading provider of critical products and services across multiple industries, serving over 225,000 customers in more than 180 countries.
Avantor Inc. (NYSE: AVTR) announced plans to enhance its global capacity for single-use technologies crucial in biologics and vaccine production. This expansion includes a 30% increase in manufacturing footprint and a doubling of cleanroom space across the U.S. and Europe, responding to rising demand for monoclonal antibodies, gene therapies, and COVID-19 vaccines. Recent expansions include its North Carolina facility and a new cleanroom in Devens, Massachusetts, expected by mid-year. A second European facility will also open in the Netherlands, ensuring efficient supply to biopharma clients.
Avantor has declared a quarterly cash dividend of $0.78 per share for its 6.250% Series A Mandatory Convertible Preferred Stock, representing a yield of 1.560%. The dividend will be paid on May 17, 2021, to shareholders on record as of April 1, 2021. This move underscores Avantor's commitment to returning value to shareholders and reflects confidence in its business model amidst ongoing global challenges.
Avantor (NYSE: AVTR) announced its acquisition of Ritter GmbH for approximately €890 million in an all-cash deal, subject to adjustments and performance milestones. Ritter is a leading manufacturer of robotic and liquid handling consumables with a market potential of nearly $7 billion. This acquisition aims to enhance Avantor's offerings in the biopharma and healthcare sectors, and is expected to be accretive to adjusted EPS immediately upon closing. The deal will be financed through available cash and term loans, with a closing anticipated in Q3 2021.
Avantor, Inc. (NYSE: AVTR) will announce its Q1 2021 financial results on April 28, 2021, after market closure. A conference call is scheduled for 5:00 p.m. ET the same day, allowing investors to discuss the results. Interested participants can join via phone or access a live webcast through the company's website. Avantor, a Fortune 500 company, provides essential products and services across the biopharma, healthcare, and advanced technologies sectors, supported by a global presence that serves over 225,000 customer locations worldwide.
Avantor (NYSE: AVTR) announced a credit rating upgrade from Moody's Investor Services to 'Ba3' with a stable outlook, following similar upgrades from Fitch Ratings and S&P Global Ratings. This rating reflects Avantor's strong performance and resilience during challenging market conditions. The company's business model remains essential to its customers across various sectors, including biopharma and advanced technologies. This upgrade is expected to enhance investor confidence and potentially lower borrowing costs, further supporting Avantor's growth initiatives.
Avantor (NYSE: AVTR) will engage in a virtual fireside chat at the Raymond James 42nd Annual Institutional Investor Conference on March 1, 2021, starting at 4:40 p.m. Eastern Time. Michael Stubblefield, President and CEO, will represent the company. Investors can access the live webcast via Avantor's investor relations page, with a replay available until March 31, 2021. Avantor is a leading provider of mission-critical products and services across biopharma, healthcare, and advanced technologies, serving over 225,000 customer locations in 180 countries.
Avantor, Inc. (NYSE: AVTR) announced a significant upgrade in its credit rating to 'BB+' with a stable outlook by S&P Global Ratings on February 10, 2021. The company's CFO, Thomas Szlosek, expressed satisfaction with this acknowledgment, highlighting their strong operational performance amidst a challenging market environment. Avantor's integrated business model has been crucial in supporting customers across various research phases. The company serves over 225,000 customer locations globally, underscoring its extensive reach and infrastructure in the life sciences and advanced technologies sectors.
Avantor, Inc. (NYSE: AVTR) reported strong financial results for Q4 and the full year 2020, showcasing resilience in a challenging environment. Q4 net sales reached $1.791 billion, up 17.5% YoY, with organic growth of 14.9%. The company generated $286 million in free cash flow. For the full year, net sales were $6.394 billion, marking a 5.8% increase, and free cash flow surged 187% to $868.2 million. Adjusted EPS rose to $0.29 in Q4, while full-year adjusted EPS increased to $0.89. The company is well-positioned as a critical partner in fighting diseases, including COVID-19.